Dechra Pharmaceuticals plc (DPH) – Analysts’ Weekly Ratings Updates

Posted by on Mar 23rd, 2016

Dechra Pharmaceuticals plc (LON: DPH) has recently received a number of price target changes and ratings updates:

  • 3/17/2016 – Dechra Pharmaceuticals plc was upgraded by analysts at Numis Securities Ltd to an “add” rating. They now have a GBX 1,285 ($18.49) price target on the stock.
  • 3/17/2016 – Dechra Pharmaceuticals plc had its price target raised by analysts at Investec from GBX 1,152 ($16.58) to GBX 1,255 ($18.06). They now have a “buy” rating on the stock.
  • 3/17/2016 – Dechra Pharmaceuticals plc was upgraded by analysts at RBC Capital to an “outperform” rating. They now have a GBX 1,320 ($19.00) price target on the stock, up previously from GBX 1,080 ($15.54).
  • 3/15/2016 – Dechra Pharmaceuticals plc had its “hold” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 1,095 ($15.76) price target on the stock.
  • 3/15/2016 – Dechra Pharmaceuticals plc had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 1,140 ($16.41) price target on the stock.
  • 3/15/2016 – Dechra Pharmaceuticals plc had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a GBX 1,280 ($18.42) price target on the stock.
  • 2/22/2016 – Dechra Pharmaceuticals plc had its “under review” rating reaffirmed by analysts at FinnCap.
  • 2/22/2016 – Dechra Pharmaceuticals plc had its “hold” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 1,095 ($15.76) price target on the stock.
  • 2/22/2016 – Dechra Pharmaceuticals plc had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 1,140 ($16.41) price target on the stock.
  • 2/22/2016 – Dechra Pharmaceuticals plc had its price target raised by analysts at Investec from GBX 1,141 ($16.42) to GBX 1,152 ($16.58). They now have a “buy” rating on the stock.
  • 2/22/2016 – Dechra Pharmaceuticals plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 1,140 ($16.41) price target on the stock.
  • 2/22/2016 – Dechra Pharmaceuticals plc was upgraded by analysts at Stifel Nicolaus to a “buy” rating. They now have a GBX 1,170 ($16.84) price target on the stock.
  • 2/16/2016 – Dechra Pharmaceuticals plc had its “sector perform” rating reaffirmed by analysts at RBC Capital. They now have a GBX 1,080 ($15.54) price target on the stock.

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 0.67% during mid-day trading on Wednesday, reaching GBX 1208.00. The company had a trading volume of 76,666 shares. Dechra Pharmaceuticals plc has a one year low of GBX 871.20 and a one year high of GBX 1,235.00. The stock has a 50 day moving average of GBX 1,112.19 and a 200-day moving average of GBX 1,022.50. The firm’s market capitalization is GBX 1.06 billion.

The company also recently disclosed a dividend, which will be paid on Wednesday, April 6th. Shareholders of record on Thursday, March 10th will be given a dividend of GBX 5.55 ($0.08) per share. The ex-dividend date is Thursday, March 10th. This represents a yield of 0.47%.

In other Dechra Pharmaceuticals plc news, insider Nesmes,Anne-Francoise sold 3,100 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of GBX 1,208 ($17.38), for a total transaction of £37,448 ($53,889.77).

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (LON:DPH) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.